Clinical features of canine nodal T‐cell lymphomas classified as CD8+ or CD4−CD8− by flow cytometry. (3rd February 2020)

• Record Type: Journal Article
• Authors: Harris, Lauren J.; Rout, Emily D.; Labadie, Julia D.; Avery, Paul R.; Fernandez, Monica; Yoshimoto, Janna; Avery, Anne C.
• Is Part Of: Veterinary and comparative oncology. Volume 18:Number 3(2020:Sep.)
• Page Start: 416
• Page End: 427
• Publication Date: 2020-02-03
• Subjects: canine -- CD4‐CD8‐ -- CD8 + -- flow Cytometry -- lymphoma -- T‐cell; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12568
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Canine T‐cell lymphoma (TCL) encompasses a heterogeneous group of diseases with variable clinical presentation, cytomorphology, immunophenotype, and biologic behaviour. The most common types of TCL in dogs involving peripheral lymph nodes include indolent T‐zone lymphoma (TZL) and biologically aggressive peripheral T‐cell lymphoma (PTCL). TCL phenotypes can be categorized by expression of the surface antigen molecules CD4 and CD8. The majority of TCL cases are CD4 +, with far fewer cases being CD8 + or CD4 − CD8 − . The clinical features of CD4 + TCLs have been previously described. The less common TCL phenotypes, however, are poorly characterized with little to no information about prognosis. In this retrospective study, we describe and correlate the presenting clinical signs, flow cytometry, and outcomes of 119 dogs diagnosed with nodal, non‐TZL, CD8 + or CD4 − CD8 − TCL by flow cytometry. Skin lesions present at the time of diagnosis were more commonly observed in the CD8 + TCL group. Mediastinal enlargement and/or hypercalcemia were more commonly seen in the CD4 − CD8 − TCL group. Dogs with either CD8 + or CD4 − CD8 − TCLs had aggressive clinical disease with median overall survival (OS) times of 198 days and 145 days, respectively. In both groups, neoplastic cell size determined by flow cytometry ranged from small to large, and large cell size was associated with shorter OS times (median OS = 61 days). Cases classified as small cell had a median OS of 257 days. Expression levels of major histocompatibility complex (MHC) class II and CD5 were highly variable among cases but were not prognostically significant in this group of patients.